Difference between revisions of "Sirolimus (Rapamune)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Autoimmune cytopenia medications" to "Category:Autoimmune cytopenias medications") |
||
| Line 17: | Line 17: | ||
[[Category:mTOR inhibitors]] | [[Category:mTOR inhibitors]] | ||
| − | [[Category:Autoimmune | + | [[Category:Autoimmune cytopenias medications]] |
[[Category:Histiocytoses medications|Erdheim-Chester disease medications]] | [[Category:Histiocytoses medications|Erdheim-Chester disease medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
[[Category:Drugs FDA approved in 1999]] | [[Category:Drugs FDA approved in 1999]] | ||
Revision as of 23:53, 14 October 2017
Mechanism of action
From the NCI Drug Dictionary: A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian target of rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production.
Diseases for which it is used
Also known as
AY 22989, RAPA, Rapamycin, SILA 9268A, SLM, WY-090217